Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Host First-Quarter Earnings Conference Call

[PR Newswire] – NORTH CHICAGO, Ill., April 7, 2016 /PRNewswire/ — AbbVie (ABBV) will announce its first-quarter 2016 financial results on Thursday, April 28, 2016, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie’s Investor Relations website at www.abbvieinvestor.com. Read more on this. AbbVie Inc. (ABBV) , with a current market cap of $95.90B, started trading this morning at $59.42. Today, shares have traded between $59.06 and $59.91 per share with its 52-week range being $45.45 to $71.60. ABBV shares are currently priced at 11.95x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.39x forward p/e ratio. And for dividend hunters, the company pays shareholders $2.28 per share annually in dividends, yielding 3.97%. According to a consensus of 16 analysts, the earnings estimate of $1.14 per share would be $0.20 better than the year-ago quarter and a $0.01 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $5.01, which would be a $0.72 improvement when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $6.03 Billion. If reported, that would be a 19.64% increase over the year-ago quarter. Recently, Societe Generale Initiated ABBV at Sell (Apr 6, 2016). Previously, Deutsche Bank Initiated ABBV at to Hold. Investors should keep in mind is that the average price target is $70.00, which is 17.81% above where the stock opened this morning. See more in (NYSE:ABBV) Similar Articles: Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds Market Update (NYSE:ABBV): AbbVie to Present at Cowen and Company 36th Annual Health Care Conference Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)